Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
The Journal of Pharmacology and Experimental Therapeutics
|
December 11, 2012
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia
Stephen E Spurgeon, Greg Coffey, Luke B Fletcher, et al.
Nature
|
December 11, 2012
High-resolution crystal structure of human protease-activated receptor 1
Cheng Zhang, Yoga Srinivasan, Daniel H Arlow, et al.
Journal of Medicinal Chemistry
|
April 2, 2004
Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists
Mukund M Mehrotra, Julie A Heath, Mark S Smyth, et al.
Antimicrobial Agents and Chemotherapy
|
June 25, 2008
Evaluation of the antimicrobial, antioxidant, and anti-inflammatory activities of hydroxychavicol for its potential use as an oral care agent
Sandeep Sharma, Inshad Ali Khan, Intzar Ali, et al.
Journal of Medicinal Chemistry
|
June 28, 2002
Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives
Kenji Matsuno, Michio Ichimura, Takao Nakajima, et al.
American Journal of Hematology
|
December 29, 2018
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study
Paul A Hamlin, Ian W Flinn, Nina Wagner-Johnston, et al.
Blood
|
September 2, 2011
Critical role for Syk in responses to vascular injury
Patrick Andre, Toshifumi Morooka, Derek Sim, et al.
Cancer Cell
|
July 19, 2002
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
Louise M Kelly, Jin-Chen Yu, Christina L Boulton, et al.
Nature Communications
|
December 18, 2023
Dissecting the genetic landscape of GPCR signaling through phenotypic profiling in C. elegans
Longjun Pu, Jing Wang, Qiongxuan Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 5, 2016
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
Matthew D Blunt, Stefan Koehrer, Rachel C Dobson, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
The Journal of Pharmacology and Experimental Therapeutics
|
December 11, 2012
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia
Stephen E Spurgeon, Greg Coffey, Luke B Fletcher, et al.
Nature
|
December 11, 2012
High-resolution crystal structure of human protease-activated receptor 1
Cheng Zhang, Yoga Srinivasan, Daniel H Arlow, et al.
Journal of Medicinal Chemistry
|
April 2, 2004
Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists
Mukund M Mehrotra, Julie A Heath, Mark S Smyth, et al.
Antimicrobial Agents and Chemotherapy
|
June 25, 2008
Evaluation of the antimicrobial, antioxidant, and anti-inflammatory activities of hydroxychavicol for its potential use as an oral care agent
Sandeep Sharma, Inshad Ali Khan, Intzar Ali, et al.
Journal of Medicinal Chemistry
|
June 28, 2002
Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 1. Synthesis, structure-activity relationship, and biological effects of a new class of quinazoline derivatives
Kenji Matsuno, Michio Ichimura, Takao Nakajima, et al.
American Journal of Hematology
|
December 29, 2018
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study
Paul A Hamlin, Ian W Flinn, Nina Wagner-Johnston, et al.
Blood
|
September 2, 2011
Critical role for Syk in responses to vascular injury
Patrick Andre, Toshifumi Morooka, Derek Sim, et al.
Cancer Cell
|
July 19, 2002
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
Louise M Kelly, Jin-Chen Yu, Christina L Boulton, et al.
Nature Communications
|
December 18, 2023
Dissecting the genetic landscape of GPCR signaling through phenotypic profiling in C. elegans
Longjun Pu, Jing Wang, Qiongxuan Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 5, 2016
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
Matthew D Blunt, Stefan Koehrer, Rachel C Dobson, et al.
Page
of 8